Product Information
GENTAMICIN 0.3% EYE DROP is a generic product labeled by Bausch & Lomb Incorporated, priced at $0.7900 per ML under NDC 24208058060. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on May 11, 1994. Its Orange Book therapeutic-equivalence code is AT.
Strength
3 mg/mL
Manufacturer
Bausch & Lomb IncorporatedNDC
24208058060
Classification
Generic
Dosage Form
SOLUTION/ DROPS
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
GENTAMICIN SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA064048FDA Approved
5/11/1994
TE Code
AT
On Market Since
5/11/1994
Pharmacological Classes
Price Statistics
The NADAC for GENTAMICIN 0.3% EYE DROP has been published 671 times since Nov 28, 2013, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7900 per ML |
|---|---|
| All-time high | $3.5187 (Nov 11, 2015) |
| All-time low | $0.5222 (Nov 20, 2024) |
| 52-week high | $0.7900 |
| 52-week low | $0.7038 |
| Median price | $0.7834 |
| Average price | $0.9708 |
| Largest weekly change | +343.5% (Oct 21, 2015) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Gentamicin Sulfate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bausch & Lomb Incorporated manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Gentamicin Sulfate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminoglycoside Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GENTAMICIN 0.3% EYE DROP?
The current National Average Drug Acquisition Cost (NADAC) for GENTAMICIN 0.3% EYE DROP, manufactured by Bausch & Lomb Incorporated, is $0.7900 per ML (NDC 24208058060), effective Sep 30, 2026.
How has the price of GENTAMICIN 0.3% EYE DROP changed over time?
Over the history we have for it, the NADAC for GENTAMICIN 0.3% EYE DROP has held within roughly two percent of its current level. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for GENTAMICIN 0.3% EYE DROP?
Since Nov 28, 2013, the NADAC for GENTAMICIN 0.3% EYE DROP has ranged from a low of $0.5222 (Nov 20, 2024) to a high of $3.5187 (Nov 11, 2015), with a median of $0.7834 per ML.
Are there cheaper alternatives to GENTAMICIN 0.3% EYE DROP?
No other NADAC-published product currently shares the active ingredient and strength of GENTAMICIN 0.3% EYE DROP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures GENTAMICIN 0.3% EYE DROP?
GENTAMICIN 0.3% EYE DROP (NDC 24208058060) is labeled by Bausch & Lomb Incorporated, and CMS classifies it as a generic product.